GILEAD SCIENCES, INC.

SEC source: 0001123292-26-000751 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,977,089

SEC source: 0001123292-26-000187 · form4.xml · derivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,384,266

Underlying: Common Stock · 3,739,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

F1 · derivative.expiration_date: The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001123292-25-000675 · form4.xml · derivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,335,000 shares

Expires not disclosed

F1 · security: The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F3 · derivative.exercise_price: The exercise price of the Series B Warrants was $0.75 per share of Common Stock. Because the Reporting Person chose to receive Prefunded Warrants in lieu of Common Stock upon exercise of the Series B Warrants, the exercise price was $0.75 less $0.0001 per share.

F4 · derivative.expiration_date: The Series B Warrants were exercisable at any time on or after November 1, 2025 and would have expired on December 2, 2025, provided that if the closing price of the Common Stock was below the exercise price on such date, the exercise price would have reset to the closing price on December 1, 2025 and the expiration time would have been extended to December 31, 2025.

SEC source: 0001123292-25-000675 · form4.xml · derivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,645,266

Underlying: Common Stock · 13,335,000 shares

Expires not disclosed

F1 · security: The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F1 · price: The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F2 · derivative.exercise_date: The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.

F2 · derivative.expiration_date: The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.

SEC source: 0001123292-25-000510 · form4.xml · derivative · entry 3

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,147,960

Underlying: Common Stock · 1,147,960 shares

Expires 2026-12-31

F1 · price: Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.

F3 · derivative.exercise_date: The Class B Warrants are exercisable at any time after November 15, 2026 and expire on December 31, 2026, provided that the Class B Warrants will automatically terminate in full and be extinguished and will no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that the Issuer has received at least $75 million in the aggregate of non-dilutive capital in connection with a collaboration agreement. A holder of the Class B Warrants may not exercise the Class B Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F3 · derivative.expiration_date: The Class B Warrants are exercisable at any time after November 15, 2026 and expire on December 31, 2026, provided that the Class B Warrants will automatically terminate in full and be extinguished and will no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that the Issuer has received at least $75 million in the aggregate of non-dilutive capital in connection with a collaboration agreement. A holder of the Class B Warrants may not exercise the Class B Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

SEC source: 0001123292-25-000510 · form4.xml · derivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,147,960

Underlying: Common Stock · 1,147,960 shares

Expires not disclosed

F1 · price: Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.

F2 · derivative.exercise_date: The Class A Warrants are exercisable at any time after the date of issuance and expire on the earlier of (i) five years from the date of issuance, or August 11, 2030, and (ii) the date that is 30 days after the public announcement that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. A holder of the Class A Warrants may not exercise the Class A Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F2 · derivative.expiration_date: The Class A Warrants are exercisable at any time after the date of issuance and expire on the earlier of (i) five years from the date of issuance, or August 11, 2030, and (ii) the date that is 30 days after the public announcement that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. A holder of the Class A Warrants may not exercise the Class A Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

SEC source: 0001123292-25-000510 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,505,391

F1 · price: Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.

SEC source: 0001062993-25-011170 · form4.xml · derivative · entry 4

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,335,000

Underlying: Common Stock · 13,335,000 shares

Expires not disclosed

F1 · security: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F1 · price: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F5 · derivative.exercise_date: The Series C Warrants are exercisable at any time on or after June 1, 2026 and expire on the earlier of (i) December 2, 2026 and (ii) the expiration time of the Series B Warrants held by the reporting person to the extent that the corresponding Series B Warrants expire without being exercised, but with respect to only that number of Series C Warrants that is equal to the number of Series B Warrants that expire without being exercised. In addition, if the closing price of the Common Stock is below the exercise price on December 2, 2026, the exercise price will reset to the closing price on December 1, 2026 and the expiration time will be extended to December 31, 2026.

F5 · derivative.expiration_date: The Series C Warrants are exercisable at any time on or after June 1, 2026 and expire on the earlier of (i) December 2, 2026 and (ii) the expiration time of the Series B Warrants held by the reporting person to the extent that the corresponding Series B Warrants expire without being exercised, but with respect to only that number of Series C Warrants that is equal to the number of Series B Warrants that expire without being exercised. In addition, if the closing price of the Common Stock is below the exercise price on December 2, 2026, the exercise price will reset to the closing price on December 1, 2026 and the expiration time will be extended to December 31, 2026.

SEC source: 0001062993-25-011170 · form4.xml · derivative · entry 3

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,335,000

Underlying: Common Stock · 13,335,000 shares

Expires not disclosed

F1 · security: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F1 · price: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F4 · derivative.exercise_date: The Series B Warrants are exercisable at any time on or after November 1, 2025 and expire on December 2, 2025, provided that if the closing price of the Common Stock is below the exercise price on such date, the exercise price will reset to the closing price on December 1, 2025 and the expiration time will be extended to December 31, 2025.

F4 · derivative.expiration_date: The Series B Warrants are exercisable at any time on or after November 1, 2025 and expire on December 2, 2025, provided that if the closing price of the Common Stock is below the exercise price on such date, the exercise price will reset to the closing price on December 1, 2025 and the expiration time will be extended to December 31, 2025.

SEC source: 0001062993-25-011170 · form4.xml · derivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,335,000

Underlying: Common Stock · 13,335,000 shares

Expires not disclosed

F1 · security: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F1 · price: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F3 · derivative.exercise_date: The Series A Warrants will be exercisable at any time on or after the earlier of (i) December 1, 2025 and (ii) the trading day immediately following a period of five consecutive trading days on which the closing price of the Common Stock is a minimum of $1.50 per share and will expire on the earlier of (A) June 5, 2030 and (B) immediately upon exercise of the reporting person's Prefunded Warrants issued on June 5, 2025 if such exercise is prior to December 1, 2025, but with respect to only that number of Series A Warrants that is equal to the number of Prefunded Warrants that are exercised.

F3 · derivative.expiration_date: The Series A Warrants will be exercisable at any time on or after the earlier of (i) December 1, 2025 and (ii) the trading day immediately following a period of five consecutive trading days on which the closing price of the Common Stock is a minimum of $1.50 per share and will expire on the earlier of (A) June 5, 2030 and (B) immediately upon exercise of the reporting person's Prefunded Warrants issued on June 5, 2025 if such exercise is prior to December 1, 2025, but with respect to only that number of Series A Warrants that is equal to the number of Prefunded Warrants that are exercised.

SEC source: 0001062993-25-011170 · form4.xml · derivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,310,266

Underlying: Common Stock · 13,335,000 shares

Expires not disclosed

F1 · security: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F1 · price: Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

F2 · derivative.exercise_date: The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.

F2 · derivative.expiration_date: The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.

SEC source: 0001062993-25-003084 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,424,760

SEC source: 0000904454-24-000669 · ownership.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,209,471

SEC source: 0001062993-24-020910 · form4.xml · derivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,975,266

Underlying: Common Stock · 6,092,816 shares

Expires not disclosed

F1 · derivative.exercise_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

F1 · derivative.expiration_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001062993-24-020910 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,105,451

SEC source: 0000904454-24-000391 · ownership.xml · derivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,500

Underlying: Common Stock · 179,500 shares

Expires 2029-06-18

F1 · price: Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 179,500 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), and a warrant to purchase 179,500 shares of Common Stock (the "Warrant") at a combined price of $15.46 per share of Common Stock and accompanying warrant.

F2 · derivative.exercise_date: The Warrant is exercisable at any time after the date of issuance and expires on June 18, 2029. A holder of the Warrant may not exercise the Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F2 · derivative.expiration_date: The Warrant is exercisable at any time after the date of issuance and expires on June 18, 2029. A holder of the Warrant may not exercise the Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

SEC source: 0000904454-24-000391 · ownership.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,268,972

F1 · price: Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 179,500 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), and a warrant to purchase 179,500 shares of Common Stock (the "Warrant") at a combined price of $15.46 per share of Common Stock and accompanying warrant.

SEC source: 0001062993-24-008004 · form4.xml · derivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,882,450

Underlying: Common Stock · 3,882,450 shares

Expires not disclosed

F1 · derivative.exercise_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

F1 · derivative.expiration_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001062993-24-008004 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,345,473

SEC source: 0001062993-24-003026 · form4.xml · derivative · entry 4

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,702,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F1 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F1 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F2 · derivative.underlying_shares: Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.

SEC source: 0001062993-24-003026 · form4.xml · derivative · entry 3

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,514,083 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F1 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F1 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F2 · derivative.underlying_shares: Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.

SEC source: 0001062993-24-003026 · form4.xml · nonDerivative · entry 2

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,126,119

SEC source: 0001062993-24-003026 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,216,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.

F2 · balance_after: Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.

SEC source: 0001104659-24-008868 · tm244648-1_4seq1.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,061,124

SEC source: 0001104659-23-077015 · tm2320354-1_4seq1.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,823,029

SEC source: 0001062993-23-014111 · form4.xml · nonDerivative · entry 1

GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,635,286

SEC source: 0001104659-21-010972 · a4.xml · nonDerivative · entry 1

GILEAD SCIENCES INC · CIK 0000882095 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,913,029

SEC source: 0001181431-06-061197 · rrd134438.xml · derivative · entry 3

GILEAD SCIENCES INC · CIK 0000882095 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 745,345 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into approximately 0.149 shares of common stock and each share of Series C-2 Convertible Preferred Stock automatically converted into approximately 0.125 shares of common stock. The Series C-1 and C-2 Convertible Preferred Stock conversion rates reflect the 1-for-8 reverse stock split, which became effective on October 24, 2006.

F3 · shares: Includes shares of preferred stock issued as a dividend which was paid upon conversion of the preferred stock in connection with the closing of the issuer's initial public offering.

F1 · derivative.exercise_date: Upon the closing of the issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into approximately 0.149 shares of common stock and each share of Series C-2 Convertible Preferred Stock automatically converted into approximately 0.125 shares of common stock. The Series C-1 and C-2 Convertible Preferred Stock conversion rates reflect the 1-for-8 reverse stock split, which became effective on October 24, 2006.

F2 · derivative.expiration_date: Not applicable

F3 · derivative.underlying_shares: Includes shares of preferred stock issued as a dividend which was paid upon conversion of the preferred stock in connection with the closing of the issuer's initial public offering.

SEC source: 0001181431-06-061197 · rrd134438.xml · derivative · entry 2

GILEAD SCIENCES INC · CIK 0000882095 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 370,494 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into approximately 0.149 shares of common stock and each share of Series C-2 Convertible Preferred Stock automatically converted into approximately 0.125 shares of common stock. The Series C-1 and C-2 Convertible Preferred Stock conversion rates reflect the 1-for-8 reverse stock split, which became effective on October 24, 2006.

F3 · shares: Includes shares of preferred stock issued as a dividend which was paid upon conversion of the preferred stock in connection with the closing of the issuer's initial public offering.

F1 · derivative.exercise_date: Upon the closing of the issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into approximately 0.149 shares of common stock and each share of Series C-2 Convertible Preferred Stock automatically converted into approximately 0.125 shares of common stock. The Series C-1 and C-2 Convertible Preferred Stock conversion rates reflect the 1-for-8 reverse stock split, which became effective on October 24, 2006.

F2 · derivative.expiration_date: Not applicable

F3 · derivative.underlying_shares: Includes shares of preferred stock issued as a dividend which was paid upon conversion of the preferred stock in connection with the closing of the issuer's initial public offering.

SEC source: 0001181431-06-061197 · rrd134438.xml · nonDerivative · entry 1

GILEAD SCIENCES INC · CIK 0000882095 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,115,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.